New cocktail of drugs shows promise against rare lymphoma
NCT ID NCT07542912
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a combination of three drugs—sintilimab, chidamide, and azacitidine—as a first treatment for people with early-stage extranodal NK/T-cell lymphoma, a rare blood cancer. About 30 participants will receive the drugs, and their response will guide further treatment, possibly including radiation. The goal is to see if this approach can make the cancer disappear completely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sintilimab, chidamide, and azacitidine
- What this could lead to
- If successful, this could offer a new first-line treatment option for early-stage NK/T-cell lymphoma, potentially improving complete remission rates and reducing the need for chemotherapy.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to all patients. The drug combination may cause side effects, and it's not yet known if it works better than current standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVERSE EVENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
- Learning from mistakes: a new study maps patient safety in team-based primary care
- Which method best catches hospital errors? study puts four to the test
- Immunotherapy combo may outperform chemo in rare lymphoma
- New keyhole surgery for esophageal cancer shows promise in early trial
- Which sedation is safer for TAVR? propofol vs dexmedetomidine